Active Biotech, Teva complete first patient enrollment in RRMS drug Phase III study
Laquinimod, which has crossed the blood brain barrier to potentially have a direct effect on resident CNS inflammation and neurodegeneration in animal models, is a CNS-active immunomodulator exhibiting
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.